BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 127331
Published online Jan 21, 2027. doi: 10.3748/wjg.127331
Table 1 The demographic and clinical characteristics of the enrolled patients
Baseline characteristics
VA group
VBAM group
P value
Gender (female/male)49/4341/510.238
Age, mean ± SD (years)40.86 ± 10.9638.67 ± 9.690.154
Body mass index, mean ± SD (kg/m2)23.55 ± 3.023.85 ± 3.10.506
Cigarette smoking (yes/no)11/8118/740.157
Alcohol drinking (yes/no)20/7226/660.307
Family history of gastric cancer (yes/no)8/847/850.788
Education level ≥ college (yes/no)71/2174/180.588
Dyspeptic symptoms (yes/no)29/6331/610.753
Atrophy (yes/no)27/6525/670.619
Comorbidities (yes/no)15/7713/790.624
Table 2 The eradication rates of each group
Analysis
VA group
VBAM group
1Rate difference
2Rate difference
P1 value
P2 value
ITT 95%CI92.4% (85/92) (85.1%-96.3%)91.3% (84/92) (83.8%-95.5%)1.1% (-6.8% to 9.0%)1.1% (-7.3% to 9.6%)0.7880.003
mITT 95%CI95.5% (85/89) (89.0%-98.2%)96.6% (84/87) (90.4%-98.8%)-1.1% (-6.8% to 4.7%)-1.1% (-7.9%-5.7%)0.7220.001
PP 95%CI95.4% (83/87) (88.8%-98.2%)96.4% (81/84) (90.0%-98.8%)-1.0% (-7.0% to 4.9%)-1.0% (-8.1%-6.0%)0.7340.002
Table 3 Adverse events in each group, n (%)
Safety and adherence
VA group
VBAM group
Risk ratio (95%CI)
P value
Total adverse events17 (18.5)24 (26.1)0.71 (0.41-1.23)0.215
Mild/moderate/severe13/4/017/7/0N/A0.736
Dysgeusia2 (2.2)3 (3.3)0.67 (0.11-3.90)1.000
Nausea or anorexia5 (5.4)5 (5.4)1.00 (0.30-3.34)1.000
Abdominal discomfort6 (6.5)11 (12.0)0.55 (0.21-1.41)0.203
Diarrhea4 (4.3)8 (8.7)0.50 (0.16-1.60)0.370
Constipation2 (2.2)1 (1.1)2.00 (0.18-21.67)1.000
Fatigue1 (1.1)3 (3.3)0.33 (0.04-3.15)0.613
Headache2 (2.2)2 (2.2)1.00 (0.14-6.95)1.000
Dizziness1 (1.1)9 (9.8)0.11 (0.01-0.86)0.023
Skin rash2 (2.2)1 (1.1)2.00 (0.18-21.67)1.000
Others2 (2.2)3 (3.3)0.67 (0.11-3.90)1.000
Adherence87 (94.6)84 (91.3)1.04 (0.96-1.12)0.388
Table 4 Cost-effectiveness analysis of each group from a healthcare payer perspective
Cost item
VA group (n = 92)
VBAM group (n = 92)
Drug cost (CNY)301.40477.90
Examination cost (CNY)145.11141.84
Adverse events-related cost (CNY)2.534.84
Total cost per patient (CNY)449.04624.58
Effectiveness (%)92.491.3
CER (CNY per successfully eradicated patient)485.97 684.10
ICER (CNY per additional successfully eradicated patient)-15958.18-


Write to the Help Desk